Multiple sclerosis (MS) is a disease with unknown cause characterized by inflammation and demyelination in the central nervous system. Although an autoimmune pathogenesis has been suggested, there are no conclusive data on the number of T cells autoreactive with myelin antigens in MS compared to controls. We showed that T lymphocytes secreting interferony in response to possible target autoantigens are severalfold more common among PBL mononuclear cells in patients with MS than in patients with aseptic meningitis and tension headache. On average T cells reactive with myelin basic protein (MBP), two different MBP peptides, or with proteolipid protein amounted to 2.7-5.2/105 PBL from MS patients. MBPreactive T cells were still more frequent among mononuclear cells isolated from the cerebrospinal fluid (CSF; 185/10O CSF cells). We concluded that T cells reactive with myelin autoantigens are strongly increased in MS. This approach to detect them could allow definition of immunodominant T cell epitopes in individual MS patients, and thereby enable further development towards specific immunotherapy. (J. Clin. Invest. 1990. 86:981-985.)
Introduction
An autoimmune pathogenesis for multiple sclerosis (MS)' has been suggested due to clinico-pathological similarities with experimental allergic encephalomyelitis (EAE). Induction of EAE depends on CD4' T cells that are autoreactive with myelin proteins (1) . Myelin basic protein (MBP) (2) and proteolipid protein (PLP) (3, 4) have both been shown to be encephalitogenic. Previous data on T cell reactivities to myelin antigens in MS (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) are partly inconsistent. One reason for failures to detect such reactivities (7) (8) (9) may be that T cells recognizing myelin antigens constitute a minute proportion of the circulating T cells. Even in EAE, the number of MBP reactive T cells were as low as 3-4/1 1" lymphocytes when isolated at the target (16) . In MS, nonselective T cell cloning with lectins shows no myelin reactivity (7, 8, 10) but is readily demonstrable in culture conditions selecting for T cell reactivity against MBP (6, 8, (11) (12) (13) 15) . Since MBP reactive T cells also have been cloned from healthy individuals (5, 12 ) the relevance ofthese observations is unclear. However, selected T cell cloning does not generally allow quantitation of T cell responses, which may be necessary to evaluate their importance. We were able to circumvent these problems by taking advantage of the fact that T cells may secrete IFN-y in response to the presented antigen (17) . By applying an immunospot assay where such cells can be counted (18, 19) it was possible to estimate the number of T cells reactive with autoantigens, in this case different myelin antigens, both in MS patients and controls. Furthermore, this particular cytokine is of potential importance as effector molecule in MS. A therapeutic trial in MS with systemic administration ofIFN-y led to exacerbations and general immune activation (20) .
Since the immune response in neuroinflammatory diseases have been shown to be compartmentalized to the target for immune attack (21- To control wells for each patient the antigen was omitted. MBP (26) and PLP (27) were prepared from bovine brain. PLP was free from any MBP contamination as checked by Western blot (28) and employing a rat polyclonal antiserum against MBP. We had access to two different synthetic peptides ofMBP. We arbitrarily named the peptides P4 and P6, and their respective amino acid sequences corresponded to 132-150 and 174-191 of mouse MBP (29 5 and 6, and encephalitogenic in guinea pig) (29) , and P6 (amino acid residues 174-191, part of MBP exons 6 and 7, and no described encephalitogenicity) (29) . As shown in Table I , the group of MS patients had -10-fold higher numbers ofT cells recognizing these peptides as compared with the two control groups. In Fig. 1 , antigen reactivities in individual MS patients are plotted. Most patients showed similar reactivity to the two different peptides, however, a few patients showed a preferential but not exclusive reactivity to one of the peptides. There was generally a higher response to the peptides than to native MBP. Due to the limited numbers ofCSF cells available for analysis, only MBP reactive specific memory T cells could be examined (Table I ; Fig. 2) . Again, the number of spots obtained from culture wells with added MBP exceeding those with no added antigen were calculated from samples of individual patients. In this way, the number of MBP reactive T cells were on respect from headache patients. In CSF, however, MS patients had a marked increase in numbers ofthese cells, while patients with AM did not differ from those with headache (Table II) . In view of an -60-fold higher CSF mononuclear cell count in AM compared with headache patients, it can be concluded that AM patients have a prominent increase in IFN-y secreting cells in CSF. It is also interesting how patients with headache devoid of organic CNS disease signs, showed some cells that produced IFN-y (Table II) .
Discussion
This study shows that the number of circulating T cells reactive with MBP is increased in MS patients as compared with patients with AM and TH. The other important putative autoantigen in MS is PLP due to its experimental encephalitogenicity (3, 4) . No significant T cell reactivity in MS with this antigen has previously been found (9, 10) . We now show an 10-fold higher number ofT cells reactive with PLP in MS as compared with the control groups. These differences were not due to a generally increased capacity to produce IFN-'y in response to antigen or lectin in MS, since the numbers of T cells responding to PPD and PHA did not differ significantly between the groups of patients. The PPD response is compatible with a T cell memory towards BCG, employed as vaccine in Sweden in the age groups examined. The PHA response represents a polyclonal T cell activation that is known to promote IFN-,y production (19) . During antigen processing the native protein is cleaved into short peptides that CD4' cells recognize when presented on MHC class II molecules (30) . The CD4' T cells appear to preferentially respond to peptides that bind with high affinity to the MHC class II (31) . This may be the reason for the differences observed in encephalitogenicity of various MBP peptides in different animal strains. For example, the encephalitogenic peptide in Lewis rats comprises amino acid residues 68-88 of MBP (32) , strain 13 guinea pigs residues 1 14-122 (33) , and SJL/J mice residues 87-101 (34) and PL/J, residues 1-11 (35) . In the genetically heterogenous population of MS patients, such immunodominant epitopes (if present) may be expected to differ between individuals. If such immunodominant and putatively pathogenetic peptides could be defined for each individual MS patient, specific immunotherapy could be tried as has been done successfully in EAE (36) (37) (38) (39) . With the two arbitrarily chosen peptides used here, a few patients showed a preferential but not exclusive reactivity to one of the peptides. There was a generally higher response to the peptides than to native MBP. The reason for this is unclear. Thus, individual MS patients respond to different nervous tissue proteins, and even to different peptides within the same protein. This indicates the presence of different MBP reactive T cell clones. On the other hand, only a minor fraction of possible peptides that can be immunodominant has been examined. We currently employ the present methodology to examine T cell reactivities towards a multitude of different peptides of MBP and PLP.
In organ specific experimental autoimmune diseases such as EAE, there are indications of an enrichment of the target directed immune response to the afflicted organ (23) . In MS, we recently showed elevated numbers of plasma cells producing autoantibodies against myelin antigens in CSF, but not in blood (24) . Such a sequestration of the immune response to target may also occur for MBP-reactive T cells in MS since such cells were 70-fold more common among CSF cells than PBL. This could either be due to selective recruitment of MBP-reactive T cells to the CSF compartment or to a local clonal expansion.
Autoreactive T cells in MS may represent a primary cause of disease or may be the consequence of inflammatory CNS damage. The latter possibility may be valid at least partly since we have observed autoreactive T cells in acute cerebrovascular diseases using the same antigens and methodology (data not shown). However, this finding does not rule out a pathogenetic role of autoreactive T cells in MS. In genetically predisposed individuals, persistence of such cells at high numbers may contribute to immune-mediated tissue damage.
IFN-'y has a special interest as an effector molecule in MS. It has previously been unsettled whether its production in MS is defective, unchanged, or increased (40) . IFN-y is a potent immunoregulatory cytokine. Major effects include enhancement and induction of class I and II MHC gene expression (41) , activation of macrophages (42, 43) , and induction of molecules involved in T cell homing (44) . Cytokines such as IFN-y usually act locally, and their production in vivo is poorly reflected in body fluids such as serum or CSF. As in this study, these problems can partly be circumvented by isolating inflammatory cells and monitoring their IFN-y production in vitro after short-term culture. Ifour data with cell cultures with no antigen added represent T cells activated to IFN-y secretion in vivo, patients with MS have a marked increase in intrathecal IFN production. The antigen specificity of these in vivo activated T cells remains unknown. The occurrence of some CSF cells that produced IFN-y also in patients with headache lacking organic CNS disease, is compatible with the hypothesis that systemically activated T cells normally pass the bloodbrain barrier possibly to ensure immune surveillance of the brain (45) .
In conclusion, T cells autoreactive with different myelin components are elevated in peripheral blood and strongly enriched in CSF of patients with MS. A future use of a broad spectrum ofpeptide antigens to detect autoreactive T cells may allow definition of immunodominant epitopes that are candidates for specific immunotherapy in individual patients. We also expect that the single cell assay may be useful for definition of target antigens in other human diseases in which autoimmune mechanisms are suspected to operate.
